{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:17:59Z","timestamp":1790014679952,"version":"4.0.1"},"reference-count":73,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["21-74-20093"],"award-info":[{"award-number":["21-74-20093"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Materials"],"abstract":"<jats:p>Diflunisal is a well-known drug for the treatment of rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and colon cancer. This molecule belongs to the group of nonsteroidal anti-inflammatory drugs (NSAID) and thus possesses serious side effects such as cardiovascular diseases risk development, renal injury, and hepatic reactions. The last clinical data demonstrated that diflunisal is one of the recognized drugs for the treatment of cardiac amyloidosis and possesses a survival benefit similar to that of clinically approved tafamidis. Diflunisal stabilizes the transthyretin (TTR) tetramer and prevents the misfolding of monomers and dimers from forming amyloid deposits in the heart. To avoid serious side effects of diflunisal, the various delivery systems have been developed. In the present review, attention is given to the recent development of diflunisal-loaded delivery systems, its technology, release profiles, and effectiveness.<\/jats:p>","DOI":"10.3390\/ma14216687","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T20:41:14Z","timestamp":1636317674000},"page":"6687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Diflunisal Targeted Delivery Systems: A Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-5709","authenticated-orcid":false,"given":"Petr","family":"Snetkov","sequence":"first","affiliation":[{"name":"Center of Chemical Engineering, ITMO University, Kronverkskiy Prospekt, 49A, 197101 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-0251","authenticated-orcid":false,"given":"Svetlana","family":"Morozkina","sequence":"additional","affiliation":[{"name":"Center of Chemical Engineering, ITMO University, Kronverkskiy Prospekt, 49A, 197101 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-1224","authenticated-orcid":false,"given":"Roman","family":"Olekhnovich","sequence":"additional","affiliation":[{"name":"Center of Chemical Engineering, ITMO University, Kronverkskiy Prospekt, 49A, 197101 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-2639","authenticated-orcid":false,"given":"Mayya","family":"Uspenskaya","sequence":"additional","affiliation":[{"name":"Center of Chemical Engineering, ITMO University, Kronverkskiy Prospekt, 49A, 197101 Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1111\/j.1365-2125.1977.tb04508.x","article-title":"Discovery of diflunisal","volume":"4","author":"Hannah","year":"1977","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_2","unstructured":"Kreutz, W. (2006). Diflunisal for the Treatment of Cancer. (20060293390), U.S. Patent."},{"key":"ref_3","unstructured":"Entellas, C.M., Insa, B.R., Reig, B.N., and Gavalda, B.N. (2020). Therapy for Transthyretin-Associated Amyloidosis. (2020390733A1), U.S. Patent."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13506129.2012.678509","article-title":"The Diflunisal Trial: Study accrual and drug tolerance","volume":"19","author":"Berk","year":"2012","journal-title":"Amyloid"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Diflunisal Trial, Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: A single center\u2019s experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR Cardiac Amyloidosis","volume":"18","author":"Helmke","year":"2012","journal-title":"Congest. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e004769","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yadav, J.D., Othee, H., Chan, K.A., Man, D.C., Belliveau, P.P., and Towle, J. (2021). Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies. Ann. Pharmacother.","DOI":"10.1177\/10600280211000351"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000001004","article-title":"A Review of Novel Agents and Clinical Considerations in Patients with ATTR Cardiac Amyloidosis","volume":"77","author":"Benbrahim","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/bega.2001.0229","article-title":"Pathogenesis of NSAID-induced gastroduodenal mucosal injury","volume":"15","author":"Wallace","year":"2001","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"ref_16","first-page":"3S","article-title":"Chemical and pharmacological properties of diflunisal","volume":"2","author":"Shen","year":"1983","journal-title":"Pharmacotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-60761-609-2_3","article-title":"Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting","volume":"624","author":"Greish","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/C7TB03160B","article-title":"Magnetic lipid nanocapsules (MLNCs): Self-assembled lipid-based nanoconstruct for non-invasive theranostic applications","volume":"6","author":"Nandwana","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"ref_19","first-page":"57","article-title":"Polymers in pharmaceutical drug delivery system: A review","volume":"14","author":"Gandhi","year":"2012","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Deng, S., Gigliobianco, M.R., Censi, R., and Di Martino, P. (2020). Polymeric Nanocapsules as Nanotechnological Alternative for Drug Delivery System: Current Status, Challenges and Opportunities. Nanomaterials, 10.","DOI":"10.3390\/nano10050847"},{"key":"ref_21","first-page":"38","article-title":"Engineering, on-demand manufacturing, and scaling-up of polymeric nanocapsules","volume":"4","author":"Alonso","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1039\/c2cs15296g","article-title":"Polymeric multilayer capsules for drug delivery","volume":"41","author":"Hoogenboom","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jor.24948","article-title":"Diflunisal-loaded poly(propylene sulfide)nanoparticles decrease S. aureus-mediated bone destruction during osteomyelitis","volume":"39","author":"Ford","year":"2021","journal-title":"J. Orthop. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2019.08.038","article-title":"Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease","volume":"311","author":"Vanderburgh","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/02652048.2016.1216189","article-title":"Formulation, characterisation and in vivo evaluation of lipid-based nanocarrier for topical delivery of diflunisal","volume":"33","author":"Amanpreet","year":"2016","journal-title":"J. Microencapsul."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Roch\u00edn-Wong, S., Rosas-Durazo, A., Zavala-Rivera, P., Maldonado, A., Mart\u00ednez-Barbosa, M.E., V\u00e9laz, I., and T\u00e1nori, J. (2018). Drug Release Properties of Diflunisal from Layer-By-Layer Self-Assembled \u03ba-Carrageenan\/Chitosan Nanocapsules: Effect of Deposited Layers. Polymers, 10.","DOI":"10.3390\/polym10070760"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.3390\/ijms11093298","article-title":"Materials for Pharmaceutical Dosage Forms: Molecular Pharmaceutics and Controlled Release Drug Delivery Aspects","volume":"11","author":"Mansour","year":"2010","journal-title":"Int. J. Mol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Naz, S., Shamoon, M., Wang, R., Zhang, L., Zhou, J., and Chen, J. (2019). Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040965"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10717540490265252","article-title":"Drug Delivery Devices Based on Mesoporous Silicate","volume":"11","author":"Cavallaro","year":"2004","journal-title":"Drug Deliv."},{"key":"ref_30","first-page":"642","article-title":"As a Review on Hydrogels as Drug Delivery in the Pharmaceutical Field","volume":"1","author":"Bindu","year":"2012","journal-title":"Int. J. Pharm. Chem. Sci."},{"key":"ref_31","first-page":"1175","article-title":"Hydrogels as potential drug delivery systems","volume":"3","author":"Amin","year":"2009","journal-title":"Sci. Res. Essays"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Larra\u00f1eta, E., Stewart, S., Ervine, M., Al-Kasasbeh, R., and Donnelly, R.F. (2018). Hydrogels for Hydrophobic Drug Delivery. Classification, Synthesis and Applications. J. Funct. Biomater., 9.","DOI":"10.3390\/jfb9010013"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16071","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/03639045.2013.828219","article-title":"Recent advances in gel Technologies for topical and transdermal drug delivery. Drug development and industrial pharmacy","volume":"40","author":"Rehman","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_35","first-page":"e59636","article-title":"A Freeze-Thawing Method to Prepare Chitosan-Poly(vinyl alcohol) Hydrogels Without Crosslinking Agents and Diflunisal Release Studies","volume":"155","year":"2020","journal-title":"J. Vis. Exp."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/03639045.2013.850711","article-title":"An insight on human skin penetration of diflunisal: Lipogel versus hydrogel microemulsion","volume":"41","author":"Sallam","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/03639045.2012.692476","article-title":"A modern approach for controlled transdermal delivery of diflunisal: Optimization and in vivo evaluation","volume":"39","author":"Sallam","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijpharm.2006.01.010","article-title":"pH-Sensitive hydrogels based on bovine serum albumin for oral drug delivery","volume":"312","author":"Iemma","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ddr.21452","article-title":"Cyclodextrin complexes: Perspective from drug delivery and formulation","volume":"79","author":"Jacob","year":"2018","journal-title":"Drug Dev. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.drudis.2015.11.017","article-title":"Cyclodextrins in pharmaceutical formulations I: Structure and physicochemical properties, formation of complexes, and types of complex","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bcpt.12917","article-title":"Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery","volume":"122","author":"Muankaew","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00656401","article-title":"The inclusion of the drug diflunisal by alpha-and beta-cyclodextrins. A nuclear magnetic resonance and ultraviolet spectroscopic study","volume":"5","author":"Lincoln","year":"1987","journal-title":"J. Incl. Phenom."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00663051","article-title":"The inclusion of diflunisal by \u03b3-cyclodextrin and permethylated \u03b2-cyclodextrin. A UV-visible and 19F nuclear magnetic resonance spectroscopic study","volume":"6","author":"Lincoln","year":"1988","journal-title":"J. Incl. Phenom."},{"key":"ref_44","first-page":"2697","article-title":"The inclusion of diflunisal by \u03b1- and \u03b2-cyclodextrins. A 19F Nuclear magnetic resonance and spectrophotometric study","volume":"83","author":"Lincoln","year":"1987","journal-title":"J. Chem. Soc. Faraday Trans. 1 Phys. Chem. Condens. Phases"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0928-0987(98)00035-9","article-title":"Studies on the interaction of diflunisal ion with cyclodextrins using ion-selective electrode potentiometry","volume":"7","author":"Sideris","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bashir, M., Syed, H.K., Asghar, S., Irfan, M., Almalki, W.H., Menshawi, S.A., Khan, I.U., Shah, P.A., Khalid, I., and Ahmad, J. (2020). Effect of Hydrophilic Polymers on Complexation Efficiency of Cyclodextrins in Enhancing Solubility and Release of Diflunisal. Polymers, 12.","DOI":"10.3390\/polym12071564"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.cclet.2017.04.001","article-title":"Crystalline inclusion complexes formed between the drug diflunisal and block copolymers","volume":"28","author":"Zhong","year":"2017","journal-title":"Chin. Chem. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cai, M., Chen, G., Qin, L., Qu, C., Dong, X., Ni, J., and Yin, X. (2020). Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030232"},{"key":"ref_49","first-page":"103","article-title":"Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications","volume":"12","author":"Sun","year":"2020","journal-title":"NanoMicro Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1039\/D0TB00599A","article-title":"A tumor-sensitive biological metal-organic complex for drug delivery and cancer therapy","volume":"8","author":"Jiang","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13761","DOI":"10.1039\/C8DT03448F","article-title":"Diflunisal-adjoined cobalt (III)-polypyridyl complexes as anti-cancer stem cell agents","volume":"47","author":"Abe","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jinorgbio.2011.09.004","article-title":"Non-steroidal anti-inflammatory drug diflunisal interacting with Cu (II). Structure and biological features","volume":"105","author":"Fountoulaki","year":"2011","journal-title":"J. Inorg. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1039\/C6CC02943D","article-title":"Pharmaceutical cocrystals: Walking the talk","volume":"52","author":"Bolla","year":"2016","journal-title":"Chem. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Karagianni, A., Malamatari, M., and Kachrimanis, K. (2018). Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10010018"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.apsb.2021.03.030","article-title":"Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Tan, J., Liu, J., and Ran, L. (2021). A Review of Pharmaceutical Nano-Cocrystals: A Novel Strategy to Improve the Chemical and Physical Properties for Poorly Soluble Drugs. Crystals, 11.","DOI":"10.3390\/cryst11050463"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1021\/cg200288b","article-title":"Pyrazinamide-Diflunisal: A New Dual-Drug Co-Crystal","volume":"11","author":"Castro","year":"2011","journal-title":"Cryst. Growth Des."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/op400182k","article-title":"Pharmaceutical cocrystals of diflunisal with nicotinamide or isonicotinamide","volume":"17","author":"Wang","year":"2013","journal-title":"Org. Process Res. Dev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"118265","DOI":"10.1016\/j.saa.2020.118265","article-title":"Solid phase drug-drug pharmaceutical co-crystal formed between pyrazinamide and diflunisal: Structural characterization based on terahertz\/Raman spectroscopy combining with DFT calculation","volume":"234","author":"Wu","year":"2020","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_60","unstructured":"Perlovich, G.L., Manin, A.N., Manin, N.G., Surov, A.O., and Voronin, A.P. (2015). Co-Crystalline Form of Theophylline with Diflunisal or Diclofenac. (RU2542100C1)."},{"key":"ref_61","unstructured":"Perlovich, G.L., Manin, A.N., and Drozd, K.V. (2017). Diflunisal Co-Crystalline. (RU2617849C1)."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4333\/KPS.2011.41.3.125","article-title":"Solid Dispersions as a Drug Delivery System","volume":"41","author":"Kim","year":"2011","journal-title":"J. Pharm. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.15406\/japlr.2019.08.00326","article-title":"Solid dispersions: A technology for improving bioavailability","volume":"8","author":"Sharma","year":"2019","journal-title":"J. Anal. Pharm. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0378-5173(89)90195-6","article-title":"Characterization of a diflunisal polyethylene glycol solid dispersion system","volume":"51","author":"Najib","year":"1989","journal-title":"Int. J. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03189324","article-title":"Dissolution kinetics for coprecipitates of diflunisal with PVP K30","volume":"23","author":"Martin","year":"1998","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-5173(01)00597-X","article-title":"Preparation, characterisation and photosensitivity studies of solid dispersions of diflunisal and Eudragit RS100\u00ae and RL100\u00ae","volume":"218","author":"Pignatello","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21608\/bfsa.2014.62620","article-title":"Formulation and evaluation of a colon drug delivery system containing diflunisal","volume":"37","author":"Donia","year":"2014","journal-title":"Bull. Pharm. Sci. Assiut"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Chis, A.A., Dobrea, C., Morgovan, C., Arseniu, A.M., Rus, L.L., Butuca, A., Juncan, A.M., Totan, M., Vonica-Tincu, A.L., and Cormos, G. (2020). Applications and Limitations of Dendrimers in Biomedicine. Molecules, 25.","DOI":"10.3390\/molecules25173982"},{"key":"ref_69","first-page":"1","article-title":"Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications","volume":"11","author":"Kalomiraki","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8844030","DOI":"10.1155\/2021\/8844030","article-title":"Dendrimers: A New Race of Pharmaceutical Nanocarriers","volume":"2021","author":"Mittal","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ejmech.2005.06.010","article-title":"Dendrimers as potential drug carriers. Part, I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers","volume":"40","author":"Cheng","year":"2005","journal-title":"Eur. J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jps.20745","article-title":"Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers","volume":"96","author":"Cheng","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2013.04.062","article-title":"Solubility enhancement of Non-Steroidal AntiInflammatory Drugs (NSAIDS) using polypolypropylene oxide core PAMAM dendrimers","volume":"451","author":"Koc","year":"2013","journal-title":"Int. J. Pharm."}],"container-title":["Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1996-1944\/14\/21\/6687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:26:47Z","timestamp":1760167607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1996-1944\/14\/21\/6687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":73,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ma14216687"],"URL":"https:\/\/doi.org\/10.3390\/ma14216687","relation":{},"ISSN":["1996-1944"],"issn-type":[{"value":"1996-1944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]}}}